Találati lista | Tudóstér

001-es BibID:	BIBFORM102494
035-os BibID:	(cikkazonosító)986 (WoS)000831789300001 (Scopus)85133021243
Első szerző:	Müller Veronika
Cím:	Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant / Veronika Müller, Lorinc Polivka, Istvan Valyi-Nagy, Alexandra Nagy, Zoltan Szekanecz, Krisztina Bogos, Hajnalka Vago, Anita Kamondi, Ferenc Fekete, Janos Szlavik, Jeno Elek, György Surján, Orsolya Surján, Péter Nagy, Zsuzsa Schaff, Cecília Müller, Zoltan Kiss, Miklós Kásler
Dátum:	2022
ISSN:	2076-393X
Megjegyzések:	Background: SARS-CoV-2 infections are associated with an increased risk of hospital admissions especially in the elderly (age >= 65 years) and people with multiple comorbid conditions. (2) Methods: We investigated the effect of additional booster vaccinations following the primary vaccination series of mRNA, inactivated whole virus, or vector vaccines on infections with the SARS-CoV-2 delta variant in the total Hungarian elderly population. The infection, hospital admission, and 28-day all-cause mortality of elderly population was assessed. (3) Results: A total of 1,984,176 people fulfilled the criteria of elderly including 299,216 unvaccinated individuals, while 1,037,069 had completed primary vaccination and 587,150 had obtained an additional booster. The primary vaccination series reduced the risk of infection by 48.88%, the risk of hospital admission by 71.55%, and mortality by 79.87%. The booster vaccination had an additional benefit, as the risk of infection, hospital admission, and all-cause mortality were even lower (82.95%; 92.71%; and 94.24%, respectively). Vaccinated patients needing hospitalization suffered significantly more comorbid conditions, indicating a more vulnerable population. (4) Conclusions: Our data confirmed that the primary vaccination series and especially the booster vaccination significantly reduced the risk of the SARS-CoV-2 delta-variant-associated hospital admission and 28-day all-cause mortality in the elderly despite significantly more severe comorbid conditions.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk SARS-CoV-2 infection delta variant vaccine effectiveness mortality hospitalization elderly comorbidities
Megjelenés:	Vaccines. - 10 : 7 (2022), p. 1-9. -
További szerzők:	Polivka Lőrinc Vályi-Nagy István Nagy Alexandra Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Bogos Krisztina Vágó Hajnalka (1972-) (orvos) Kamondi Anita Fekete Ferenc Szlávik János Elek Jenő Surján György Surján Orsolya Nagy Péter (1976-) (vegyész) Schaff Zsuzsa Müller Cecília Kiss Zoltán Kásler Miklós
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM116830
035-os BibID:	(cikkazonosító)1786 (WoS)001131056200001 (Scopus)85180662724
Első szerző:	Polivka Lőrinc
Cím:	Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients : lessons from the Delta Variant / Lörinc Polivka, Istvan Valyi-Nagy, Zoltan Szekanecz, Krisztina Bogos, Hajnalka Vago, Anita Kamondi, Ferenc Fekete, Janos Szlavik, György Surjan, Orsolya Surjan, Peter Nagy, Zsuzsa Schaff, Zoltan Kiss, Cecilia Müller, Miklos Kasler, Veronika Müller
Dátum:	2023
ISSN:	2076-393X
Megjegyzések:	Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection against infection and severe disease can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections. The Hungarian COVID-19 registry was retrospectively investigated for risk of infection and hospitalization by time since the last vaccination, and vaccine effectiveness (VE) was calculated in adults with COPD diagnosis and an exact-matched control group during the Delta variant of concern (VOC) wave in Hungary (September-December 2021). For the matching, sex, age, major co-morbidities, vaccination status, and prior infection data were obtained on 23 August 2021. The study population included 373,962 cases divided into COPD patients (age: 66.67 +/- 12.66) and a 1:1 matched group (age: 66.73 +/- 12.67). In both groups, the female/male ratio was 52.2:47.7, respectively. Among the unvaccinated, there was no difference between groups in risk for infection or hospitalization. Regarding vaccinated cases, in the COPD group, a slightly faster decline in effectiveness was noted for hospitalization prevention, although in both groups, the vaccine lost its significant effect between 215 and 240 days after the last dose of vaccination. Based on a time-stratified multivariate Cox analysis of the vaccinated cases, the hazard was constantly higher in the COPD group, with an HR of 1.09 (95%: 1.05-1.14) for infection and 1.87 (95% CI: 1.59-2.19) for hospitalization. In our study, COPD patients displayed lower vaccine effectiveness against SARS-CoV-2 infection and hospitalization but a similar waning trajectory, as vaccines lost their preventive effect after 215 days. These data emphasize revaccination measures in the COPD patient population.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk COVID-19 COPD vaccine effectiveness VE waning
Megjelenés:	Vaccines. - 11 : 12 (2023), p. 1-12. -
További szerzők:	Vályi-Nagy István Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Bogos Krisztina Vágó Hajnalka (1972-) (orvos) Kamondi Anita Fekete Ferenc Szlávik János Surján György Surján Orsolya Nagy Péter Schaff Zsuzsa Kiss Zoltán Müller Cecília Kásler Miklós Müller Veronika
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: